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Therapeutic Advances in Respiratory Disease
Ivacaftor, a cystic fibrosis transmembrane con-
ductance regulator (CFTR) potentiator, is 
approved for the treatment of patients with cystic 
fibrosis (CF) with the G551D mutation aged 6 
years or older. To evaluate the efficacy of this 
CFTR-modulating therapy (CFTR-MT) bio-
markers such as sweat chloride (SC), nasal poten-
tial difference (NPD) and intestinal current 
measurement (ICM) have been implemented.
All three biomarkers play a crucial role in diag-
nosing CF, especially in questionable cases. 
Experiences in applying several CFTR measure-
ments in individual patients to evaluate a 
CFTR-MT have been scarce so far.
SC is a highly feasible biomarker for assessing 
CFTR function in an organ not involved in 
chronic inflammation/infection and can reflect 
even small changes. NPD has the advantage of 
representing CFTR function in the respiratory 
system, the organ most responsible for survival in 
CF. ICM is feasible, but does not represent CFTR 
in the respiratory system and some patients are 
reluctant to undergo rectal biopsies [DeBoeck, 
2013].
A review article by DeBoeck and colleagues pro-
vided useful information to support the promo-
tion of these CFTR biomarkers to surrogate 
endpoints in clinical trials and to guide further 
research in this area [DeBoeck et  al. 2013]. We 
discuss the practical use of these biomarkers in 
‘real-life’ situations for evaluating the efficacy of 
personalized CFTR-MT in a specific patient. We 
report the results of these biomarkers in a small 
sample size survey of eight patients with CF 
receiving ivacaftor and discuss the difficulty in 
identifying clear responders to CFTR-MT in 
view of the fact that long-term side effects are still 
unknown.
Eight patients (G551D heterozygotes; aged 11–41 
years) were treated with ivacaftor as a CFTR-MT. 
To evaluate efficacy, we implemented a surveillance 
protocol including forced expiratory volume in 
1 second (FEV1) and the biomarkers described 
above (EC-approved; NPD-performance [after 
certification] according to the standard operating 
procedures [SOP] of the Therapeutics Development 
Network [TDN], Bethesda, MA, USA; ICM [only 
Giessen] [after certification] according to the 
European Cystic Fibrosis Society-TDN-SOP).
All patients showed marked, constant improve-
ment in SC; seven patients changed their category 
of CF (chloride > 60 mmol/L) to intermediate 
(30–60 mmol/L) or normal (< 30 mmol/L) (Table 
1). In ICM, two patients demonstrated an improve-
ment in CFTR function from CF category to the 
normal category. Further ICM measurements 
were denied. In NPD, slight improvements within 
the pathological category were observed in three 
patients. In six patients the absolute FEV1 improved 
by more than 5%.
We observed marked improvements in SC and ICM 
with changes in category (pathological to interme-
diate or normal in SC and pathological to normal in 
ICM), whereas NPD did not show this clear 
improvement (at most, slight improvement within 
the pathological category); however, the evaluation 
of ICMs has to be interpreted cautiously as only two 
measurements could be performed. In the ivacaftor 
trials, FEV1 and SC showed marked improvements 
[Ramsey et al. 2011], but changes in SC were more 
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impressive than changes in NPD. None of the NPD 
measures correlated with changes in FEV1 nor did 
SC [Rowe et al. 2013]. ICM was not performed.
When SC improves, particularly with a change in 
category, we tend to be convinced of clinical efficacy 
because SC reflects CFTR function without con-
founding factors. We might even conclude that SC 
may reflect compliance because pharmacokinetics 
are not routinely measured clinically. One patient 
remained in the pathological category (chloride 61 + 
67 mmol/L) and stopped ivacaftor after some 
months due to severe anxiety about future side 
effects. We hypothesized that reduced compliance 
could explain the lack of marked SC improvement.
FEV1 is influenced by ‘physiological’, ‘genetic’ and 
‘environmental’ factors which are not influenced 
by CFTR-MT [DeBoeck et al. 2013]. Only 50% 
of FEV1 variability can be explained by inherited 
factors, including CFTR [Stanke et  al. 2011]; 
other important factors include genetic modifiers, 
epigenetic effects and environmental determinants. 
Our inconsistent FEV1 results may reflect this indi-
vidual course of disease. The lack of improvement 
in NPD (respiratory epithelium) could also be 
explained by these factors, for example, inflamma-
tion, scarring or passive cigarette-smoke exposure. 
Wilschanski and colleagues examined healthy con-
trols, men with congenital bilateral aplasia of the 
vas deferens, pancreatic-sufficient CF and pancre-
atic-insufficient CF patients according to the gen-
otype–phenotype relationship between SC and 
NPD, and demonstrated that SC seems to be more 
sensitive than NPD towards the severe end of the 
spectrum [Wilschanski et al. 2006].
Several questions remain, including: which 
biomarker(s) should be used to suggest clinical 
benefit? How many biomarkers should show 
which degree of improvement or even a change in 
category? Fortunately, standardization of these 
techniques has advanced with SOPs and certifica-
tion processes, but we lack validated standards for 
interpreting the results, for example, for NPD 
and ICM [Naehrlich et al. 2014]. In some studies, 
group-specific differences may be statistically sig-
nificant, but how can we define clinical relevance 
in individual patients during CFTR-MT?
To date, no biomarker has been found to correlate 
with FEV1. Previous attempts to correlate SC with 
Table 1. Demographics and clinical CFTR-response in eight patients with one G551D mutation receiving ivacaftor treatment.
Age
(years)
Mutation Gender Pseudomonas 
aeruginosa 
status
FEV1 predicted
(%)
Sweat 
chloride
NPD CFTR response ICM CFTR 
response
(mmol/L) average Δ0Cl- + Iso 
(mV)
average ΔIsc 
(µA/cm2))
 Cut-off < 60 
mmol/L
Cut-off < –7.7 mV Cut-off >20 µA/
cm2
11 R709X Male Negative 116 / 121 / 111 113 / 56 / 32 −3.24 / 2.77 / −2.63 NA
16 G542X Female Negative 83 / 71 / 78 89 / 15 / 17 2.64 / 1.62 / 5.36 NA
18 F508del Male Negative 102 / 121 / 114 92 / 12 / NA −2.95 / NA / −4.56 NA
20 E60X Female Positive 81 / 83 / 52* 113 / 43 / 52 8.80 / 4.09 / 2.26 NA
25 F508del Male Negative 76 / 84 / 77 94 / 36 / 41 3.88 / 0.31 / 0.05 17.9 / 28.0 / NA
26 N1303K Male Negative 85 / 102 / 104 100 / 44 / 46 6.20 / 4.83 / 6.18 NA
30 F508del Male Positive 60 / 61 / 67 102 / 61 / 67 4.87 / 8.36 / 5.56 NA
41 F508del Female Positive 48 / 52 / 53 97 / 41 / 48 6.41 / 1.84 / 1.30 −2.12 / 43.2 / NA
In cells with three values the first value represents the baseline measurement; the second and third values represent results at 1–3 months and 
6–15 months, respectively.
Pseudomonas aeruginosa status: negative or positive during time interval of survey.
NPD CFTR response: the sum of the response to zero chloride + isoproterenol (both nostrils averaged). ICM CFTR response: the sum of the 
response to Forskolin/3-isobutyl-1-methylxanthine (IBMX) + carbachol + histamine.
Bold face numbers represent improvements in absolute FEV1% pred. that were more than 5% from baseline, noncystic fibrosis reference ranges 
for sweat chloride (< 60 mmol/L), improvement of NPD (Δ0Cl- + Iso < - 3 mV; noncystic fibrosis range < -7.7 mV) and of ICM (> 20 µA/cm2) 
[Bagheri-Hanson et al. 2014].
* pulmonary exacerbation.
CFTR: cystic fibrosis transmembrane conductance regulator; FEV1: forced expiratory volume after 1 second; ICM: intestinal current measure-
ment; NPD: nasal potential difference; NA: not applied.
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FEV1 have been unsuccessful; random variation 
or environmental factors were considered possible 
explanations [Davis et al. 2004]. In addition, it still 
remains to be determined whether changes in bio-
markers can be translated into individual patient 
mortality. Simmonds and colleagues showed that 
neither NPD nor SC was associated with increased 
survival on examining long-term survival in 
patients with homozygous F508del [Simmonds 
et  al. 2011] Furthermore, different biomarkers 
may be relevant in different pathophysiological 
processes and disease stages [Ramsey et al. 2011]. 
So how often should we measure biomarkers?
Finally, the question remains: how can we translate 
results into the efficacy/nonefficacy of an individ-
ual therapy, in terms of mortality or even long-
term survival? Even when more biomarkers are 
added to the surveillance protocol, such as body 
mass index, mucociliary clearance, beta-adrenergic 
sweat secretion rate, gastrointestinal pH and spu-
tum inflammation [Rowe et al. 2014], this question 
remains unanswered. Novel emerging clinical end-
points such as lung clearance index measurements, 
intestinal organoids, chest computed tomography 
scans or nasal cell banks might contribute to more 
insight in the future. However, clinical-relevant dif-
ferences for each method remain to be defined.
Up to now, a change in category with at least one 
biomarker might seem convincing to patients and 
CF teams to justify continuing ivacaftor, independ-
ent of changes in FEV1. Longitudinal monitoring 
of CF patients receiving ivacaftor by applying all 
CFTR functional tests might allow further insights 
into the evaluation of clinical effects until we have 
proven the relationship between biomarkers and 
survival or at least long-term benefit.
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